10 years ago, the German reimbursement system for drugs changed significantly. The AMNOG including a benefit assessment and price negotiation was launched. Threats were seen, but also opportunities - the AMNOG frame was criticized and in some aspects also changed over time. A learning system - as some say.
The speakers have worked and shaped the AMNOG process also before its implementation and have also been working since the start of it in various roles and on many different products. The presentation and discussions will show the following key aspects:
- What are key success factors for an optimal AMNOG process?
- Are there any guidances for clinical development?
- How is the benefit rating and price negotiation correlated? What are drivers?
- What can we expect in the future from the AMNOG?